Use of digital twins will be essential in accelerating the use of CAR-T in cancer treatment and mitigating the side effects, says Phesi

Date: 06. 01. 2022

Phesi creates new digital twin of patients with Cytokine Release Syndrome (CRS) as wider use of cell-based immunotherapies demands new treatments for CRS and other complications

Boston, USA, 1st June, 2022: Phesi Inc., a data-driven provider of AI-powered clinical development analytics, products and solutions, has announced the creation of a digital twin for Cytokine Release Syndrome (CRS) patients following CAR-T therapy. CAR-T immunotherapies have become widely used in treatment of lymphomas, leukemia, and multiple myeloma; this trend is expected to increase. CRS is one of the most frequent and serious side effects of CAR-T therapy and has only one FDA-approved treatment, Tocilizumab. The difficulty of conducting clinical trials for such a serious and acute condition has held back new breakthroughs. To support development efforts in this space, Phesi created the digital twin for the CRS patient population based on an analysis of 5,473 CAR-T treated patients.

“Because of the relative scarcity of CRS patients, the search for new therapies is effectively akin to evaluating a rare disease. A decade on from the first immunotherapies, it is essential new treatments are found, given that CAR-T is being applied for more indications – particularly for blood cancer,” commented Dr Gen Li, Founder and CEO, Phesi. “The rapid onset and often life-threatening nature of CRS means the traditional development approach of double-blind trials is not feasible. To overcome this barrier, the pharmaceutical industry must look to artificial intelligence and big data analysis to improve the benefit-risk ratio for CAR-T treatment. Our goal in creating this digital twin dataset that can function as a synthetic control arm is to accelerate the evaluation of treatments for CRS.”

CRS can lead to widespread organ dysfunction and is common in patients treated by infused CAR-T cells; CRS is also a serious complication of viral infections, such as SARS-CoV-2. CRS-associated mortality associated with CD19 CAR-T cell therapy remains unacceptably high at 5.4%. Phesi analyzed data from 5,473 CAR-T treated patients: 5,335 in a cohort setting and 138 with individual anonymized records. A total of 392 patients from eight cohorts enabled the construction of this digital twin of CRS patients receiving the standard of care (SOC). The distribution of CRS grades (1-4) was calculated. The CRS by grade was consistent across the eight cohorts; a more effective treatment of CAR-T related CRS would reduce high and median-grade CRS. Similar to this digital twin, a synthetic clinical trial arm should show similar CRS by grade distribution pattern.

“Today, the industry typically gathers data from individual patients, usually in a randomized, double blind, placebo-controlled setting. But in some indications, developing digital twins for a control experience is a new and more effective approach to drug development enabled by using a combination of cohort data and data from individual patients,” continued Dr Li. “By modernizing the industry’s current approach to clinical studies, Phesi can help to reduce the time it takes to find treatments for CRS and ensure CAR-T delivers the best outcomes. Importantly, the digital twin approach also makes clinical development far more patient-centric, reducing both patient and investigator site burden by eliminating the need for placebo treatments in trials.”

Dr Gen Li and Phesi will be available to discuss this digital twin approach to clinical trials at the American Society of Clinical Oncology’s annual meeting in Chicago, from June 3-7 (booth #5033). Request a meeting here: Phesi’s platform is the industry’s most powerful clinical development solution for predicting outcomes in trials, reducing protocol amendments, and improving cycle times.

For more information on how Phesi enables smarter trials and faster cures, visit:

Related news
06. 10. 2024
Global oncology trial investigator sites increase by half in five years, finds new Phesi analysis Read more
05. 14. 2024
Phesi launches predictive Patient Burden Score to improve trial efficiency, patient experience and investigator site performance Read more
05. 08. 2024
Phesi Q1 2024 Business Update Read more
02. 12. 2024
Phesi announces AI-driven Trial Accelerator™ hits critical milestone with data from 100 million patients Read more
01. 16. 2024
Phesi releases 2023 analysis of clinical development; breast cancer remains most studied disease area for third year Read more
10. 15. 2023
Phesi launches Health Check and Trial Rescue Service to save at-risk trials and bring drugs to market faster Read more